Clinical Trial

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Phase I: To evaluate the safety, tolerance and effectiveness of IAP0971 for the treatment of advanced malignant tumors. Phase II: Evaluation of IAP0971 therapy driver negative and PD-L1 positive (TPS≥50%) The initial treatment is effective in subjects with advanced or metastatic non-small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-26.
Status change: Not Yet Recruiting → Recruiting 2025-01-13
Trial Details
NCT Number NCT06581419
Lead Sponsor SUNHO（China）BioPharmaceutical CO., Ltd.
Conditions Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer
Enrollment 78 participants
Start Date 2024-12-31
Primary Completion 2029-08-01 (estimated)
Study Completion 2029-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-15